Can we find just one honest Russiacon - NO - every single one is corrupt
M.A.G.A.T's
Collins, one of President Donald Trump's strongest congressional allies, remains under investigation by the committee, which has the power to sanction lawmakers.
NEW YORK — Republican U.S. Rep. Christopher Collins of western New York state has been indicted on charges that he used inside information about a biotechnology company to make illicit stock trades.
The charges were announced and the indictment unsealed in New York City on Wednesday
.
Also charged with insider trading in the indictment is Collins' son, Cameron, and Stephen Zarsky, the father of Cameron Collins' fiancée, according to the U.S. Attorney's Office in the Southern District of New York.
In October, a congressional ethics investigation determined there was "a substantial reason to believe" Rep. Collins violated federal law when he promoted stock in Innate Immunotherapeutics using insider information. The probe made a similar finding about a 2013 meeting Collins attended at the National Institutes of Health, where he asked staff to meet with the Australian company about clinical trial designs.
M.A.G.A.T's
Collins, one of President Donald Trump's strongest congressional allies, remains under investigation by the committee, which has the power to sanction lawmakers.
NEW YORK — Republican U.S. Rep. Christopher Collins of western New York state has been indicted on charges that he used inside information about a biotechnology company to make illicit stock trades.
The charges were announced and the indictment unsealed in New York City on Wednesday
.
Also charged with insider trading in the indictment is Collins' son, Cameron, and Stephen Zarsky, the father of Cameron Collins' fiancée, according to the U.S. Attorney's Office in the Southern District of New York.
In October, a congressional ethics investigation determined there was "a substantial reason to believe" Rep. Collins violated federal law when he promoted stock in Innate Immunotherapeutics using insider information. The probe made a similar finding about a 2013 meeting Collins attended at the National Institutes of Health, where he asked staff to meet with the Australian company about clinical trial designs.
Last edited: